Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.445 HKD | +1.14% | +39.06% | -55.05% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 3,069 | 918.1 | 175 | 175 | - |
Enterprise Value (EV) 2 | 2,376 | 610.3 | 386.5 | -334.9 | -103.8 |
P/E ratio | -0.63 x | -1.88 x | -1.03 x | -0.7 x | -0.59 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | 98.5 x | 11.6 x | 3.71 x | 1.35 x | 0.44 x |
EV / Revenue | 76.2 x | 7.73 x | 3.76 x | -2.58 x | -0.26 x |
EV / EBITDA | -3.72 x | -1.4 x | -1.09 x | 0.99 x | 0.48 x |
EV / FCF | -4,011,666 x | - | - | - | - |
FCF Yield | -0% | - | - | - | - |
Price to Book | 1.02 x | 2.95 x | -9.75 x | 0.21 x | 0.32 x |
Nbr of stocks (in thousands) | 424,192 | 424,292 | 424,838 | 424,838 | - |
Reference price 3 | 8.880 | 2.450 | 0.4450 | 0.4450 | 0.4450 |
Announcement Date | 3/22/22 | 3/30/23 | 3/28/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales 1 | - | 31.16 | 78.97 | 102.9 | 130 | 397.5 |
EBITDA 1 | - | -639.4 | -436 | -353.8 | -338.6 | -214.9 |
EBIT 1 | - | -655.1 | -476.6 | -369.9 | -192.2 | -237.7 |
Operating Margin | - | -2,102.46% | -603.52% | -359.57% | -147.83% | -59.79% |
Earnings before Tax (EBT) 1 | - | -1,077 | -483.5 | -378.8 | -250.5 | -293.3 |
Net income 1 | -846 | -1,077 | -483.5 | -378.8 | -250.5 | -293.3 |
Net margin | - | -3,456.26% | -612.21% | -368.26% | -192.67% | -73.78% |
EPS 2 | -15.11 | -14.04 | -1.302 | -0.9638 | -0.6380 | -0.7515 |
Free Cash Flow | - | -592.2 | - | - | - | - |
FCF margin | - | -1,900.31% | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - |
Announcement Date | 11/30/21 | 3/22/22 | 3/30/23 | 3/28/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 4.44 | - | - |
Net Cash position 1 | - | 694 | 308 | 230 | 510 | 279 |
Leverage (Debt/EBITDA) | - | - | - | -0.0125 x | - | - |
Free Cash Flow | - | -592 | - | - | - | - |
ROE (net income / shareholders' equity) | - | -155% | -96.5% | -282% | -54.4% | -38.7% |
ROA (Net income/ Total Assets) | - | -146% | - | - | - | - |
Assets 1 | - | 739.4 | - | - | - | - |
Book Value Per Share 2 | - | 8.710 | 0.8300 | -0.1000 | 2.080 | 1.410 |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | 8.5 | - | - | - | - |
Capex / Sales | - | 27.28% | - | - | - | - |
Announcement Date | 11/30/21 | 3/22/22 | 3/30/23 | 3/28/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-55.05% | 24.15M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
+18.82% | 2.38B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B |
- Stock Market
- Equities
- 1228 Stock
- Financials CANbridge Pharmaceuticals Inc.